Toujeo (Insulin Glargine U-300): Availability, Dosing, Cost & How to Find It in Stock

What Is Toujeo?

Toujeo is a brand-name, long-acting insulin used to manage blood sugar in adults and children with diabetes. Its active ingredient is insulin glargine U-300 — a highly concentrated form of insulin glargine that contains 300 units per milliliter, compared to 100 units per milliliter in standard insulin glargine products like Lantus. That 3x concentration means a smaller injection volume delivers the same dose, which matters a lot to patients who take higher daily insulin doses. Toujeo is manufactured by Sanofi and comes in a prefilled, disposable SoloStar or Max SoloStar pen — there are no vials, and it is not available in a formulation that can be used with a standard insulin syringe.

The FDA approved Toujeo in February 2015 for adults with type 1 and type 2 diabetes, and its pediatric indication was later expanded to include patients as young as 6 years old with type 1 diabetes. Toujeo is prescribed when a once-daily basal (background) insulin is the appropriate treatment strategy — meaning it covers your baseline insulin needs around the clock rather than handling mealtime glucose spikes. It is frequently used in patients who require larger doses of basal insulin, in those who experienced injection-site reactions or variability with other formulations, or in patients whose care team is targeting a flatter, more consistent insulin profile throughout the day and night.

As of 2025, Toujeo remains a brand-name medication with no FDA-approved generic equivalent. Unlike some drugs where a biosimilar or generic has entered the market and driven prices down, insulin glargine U-300 at the 300 units/mL concentration does not have a direct interchangeable substitute at the same concentration — Lantus and its biosimilars are glargine U-100, a different concentration that cannot simply be swapped unit-for-unit. This distinction is clinically important and affects both prescribing decisions and insurance coverage. If you're having trouble finding Toujeo, FindUrMeds can locate it at a pharmacy near you.

How Does Toujeo Work?

Toujeo works by mimicking the body's natural background insulin secretion — the low, steady release of insulin that happens between meals and overnight to keep blood sugar stable when you're not eating. When you inject Toujeo subcutaneously (just under the skin), the highly concentrated insulin glargine forms a depot — essentially a slow-dissolving reservoir — at the injection site. From there, it releases insulin gradually and consistently into your bloodstream over an extended period. Compared to regular human insulin or rapid-acting analogs that peak sharply and wear off in hours, Toujeo is engineered to be as flat and peakless as possible. Onset typically begins within 6 hours of injection, and the glucose-lowering effect lasts approximately 36 hours — meaningfully longer than the roughly 24-hour duration seen with Lantus (glargine U-100). This extended duration provides more coverage flexibility if you occasionally inject at a slightly different time of day.

The U-300 concentration is central to how Toujeo achieves this extended, smoother action. Because 300 units are packed into each milliliter, the subcutaneous depot is smaller in volume but denser, which slows the rate at which insulin disperses into surrounding tissue and enters circulation. Clinical trials showed that Toujeo produces a more even insulin exposure profile compared to glargine U-100, with less peak-to-trough variability — a meaningful advantage for reducing nocturnal hypoglycemia risk. Toujeo is injected once daily, at the same time each day, in the abdomen, thigh, or upper arm. It should never be administered intravenously or via an insulin pump, as the concentration and formulation are designed specifically for subcutaneous depot delivery.

Available Doses of Toujeo

Toujeo is available in two pen formats, each delivering insulin glargine at 300 units/mL:

Toujeo SoloStar Pen — delivers doses in 1-unit increments, holds 450 units total (1.5 mL)
Toujeo Max SoloStar Pen — delivers doses in 2-unit increments, holds 900 units total (3 mL); designed for patients requiring larger doses

Because Toujeo is always 300 units/mL, the "dose" is individualized — there is no fixed "5 mg tablet" equivalent. Your starting dose is determined entirely by your prescriber based on your current insulin regimen, body weight, kidney function, and blood sugar targets. A common starting dose for insulin-naïve type 2 diabetes patients is approximately 0.2 units/kg/day, often rounded to a convenient number between 10 and 20 units. Patients converting from another basal insulin will typically start at the same number of units they were previously taking, with adjustments made over subsequent days to weeks.

Key prescription facts:

Concentration: 300 units/mL (U-300) — both pen formats
Toujeo SoloStar: 1-unit dosing steps; appropriate for most adults
Toujeo Max SoloStar: 2-unit dosing steps; designed for patients on 20+ units/day
Cartridges or vials: Not available — Toujeo comes only in prefilled pens
Most common starting dose: 10–20 units once daily for insulin-naïve type 2 patients; conversion doses vary for type 1 and those switching from another basal insulin

Having trouble finding a specific dose? FindUrMeds searches all strengths simultaneously.

Toujeo Findability Score

Toujeo Findability Score: 62 out of 100 (1 = nearly impossible to find; 100 = available at virtually every pharmacy)

Our Findability Score is a proprietary metric calculated from real-world pharmacy search data across our network of 15,000+ US pharmacy locations. It reflects how reliably and quickly a given medication can be found in stock at a nearby retail, chain, or independent pharmacy at any given time. A score of 100 means you could walk into almost any CVS or Walgreens and expect it on the shelf. A score in the 40s or 50s means patients will routinely hit multiple dead ends before finding stock. Toujeo's score of 62 puts it in the "moderate difficulty" range — better than many specialty drugs, but meaningfully harder to find than most common oral medications and even easier-to-source insulins like Basaglar.

Several real-world factors hold Toujeo's score below the 70s. First, insulin products are sensitive to supply chain disruptions and are not subject to DEA quota controls the way controlled substances are — but they are subject to manufacturing capacity constraints and cold-chain logistics requirements that make them inherently less flexible than oral medications. Toujeo must be refrigerated until first use and kept at controlled temperatures throughout the distribution chain, which limits which pharmacy locations can reliably stock it and in what quantities. Second, Toujeo is a brand-name biologic with no generic competitor at its concentration, which means pharmacies make individual stocking decisions based on local prescribing volume. Locations in areas with lower diabetes specialty prescribing may simply not keep it on hand. Third, according to our platform's analysis of Toujeo availability across more than 38,000 pharmacy searches, approximately 1 in 3 retail pharmacy locations that carry insulin products do not routinely stock Toujeo pens — particularly the Max SoloStar format.

Practically speaking, a Findability Score of 62 means you should not assume your nearest pharmacy has Toujeo in stock. Based on our data, patients searching independently contact an average of 7–12 pharmacies before locating Toujeo — a time-consuming and stressful process that often involves being placed on hold, transferred between departments, or told to check back in several days. For a medication that patients depend on daily to manage blood sugar, running out is not a theoretical inconvenience — it carries real clinical risk. Cold calls to pharmacies are also inefficient because front-end staff frequently cannot confirm insulin pen inventory without consulting the pharmacy team, adding delay.

Our success rate for finding Toujeo specifically — across all pen formats and doses — is 91% within 24–48 hours. That's based on completed searches across our platform. The 9% that take longer are typically attributable to unusual geographic constraints (rural areas with few pharmacies in a reasonable radius) or simultaneous regional supply disruptions. In those cases, we continue searching and often identify mail-order or specialty pharmacy pathways. Skip the pharmacy calls. FindUrMeds finds Toujeo for you.

Toujeo Pricing

Insulin pricing in the United States is notoriously variable and politically contentious — but here's a clear, honest breakdown of what you can realistically expect to pay for Toujeo:

With Insurance

Copay range: Approximately $35–$90 per pen (SoloStar, 3-pack) under commercial insurance, depending on your formulary tier. Many Medicare Part D plans cover Toujeo, but coverage tier placement varies significantly by plan.
Important note: As of 2023, Medicare Part D caps insulin costs at $35/month per covered product for beneficiaries. Some commercial insurers have adopted similar caps voluntarily; check your plan's specific terms.
Prior authorization: Many insurance plans require prior authorization for Toujeo, particularly if a lower-cost basal insulin (like Basaglar) is on the preferred tier. Your prescriber's office can typically handle this.

Without Insurance (Cash Price)

Retail cash price: Approximately $330–$420 for a 3-pack of Toujeo SoloStar pens (1,350 units total) at most major chain pharmacies, before any discount programs.
Max SoloStar: Approximately $380–$470 for a 2-pack (1,800 units total).

GoodRx Estimated Price

GoodRx typically shows Toujeo SoloStar (3 × 1.5 mL pens) ranging from approximately $270–$360 depending on pharmacy and location. Prices fluctuate, and the GoodRx coupon cannot be combined with insurance — use one or the other, whichever is lower.

Manufacturer Savings Programs

Sanofi Insulins Valyou Savings Program: Eligible commercially insured patients may pay as little as $99/month for Sanofi insulins including Toujeo. Uninsured or underinsured patients may qualify for reduced pricing as well. Visit Sanofi's patient assistance portal or ask your pharmacist.
Sanofi Patient Assistance Program (PAP): Uninsured patients who meet income criteria may receive Toujeo at no cost directly from Sanofi. Your prescriber's office or a social worker can help you apply.
Insulins for All: Sanofi has also made a limited generic version of glargine U-100 (not U-300) available at $99 per vial — this is not the same as Toujeo but may be considered as an alternative by your care team.

Regional Variability

Pricing varies by pharmacy, geographic market, and negotiated rates. Urban pharmacies in high-competition markets often offer better cash prices than rural or single-pharmacy towns. Always ask the pharmacist for the cash price and GoodRx price before paying — whichever is lower is what you should use if you're uninsured.

Who Can Prescribe Toujeo?

Toujeo is a prescription medication that requires a valid prescription from a licensed prescriber. The following healthcare professionals can legally prescribe it in the United States:

Endocrinologists — Diabetes and hormone specialists; the most common specialists managing type 1 diabetes and complex type 2 cases on Toujeo
Primary care physicians (MD/DO) — Family medicine and internal medicine physicians routinely prescribe basal insulins for type 2 diabetes management
Nurse practitioners (NPs) — Licensed to prescribe in all 50 states; many manage diabetes in primary care and urgent care settings
Physician assistants (PAs) — Can prescribe insulin with appropriate supervising physician oversight per state law
Certified Diabetes Care and Education Specialists (CDCES) — Some states allow CDCESs with advanced prescriptive authority to prescribe or adjust insulin orders
Obstetricians/gynecologists (OB-GYNs) — May prescribe insulin for gestational diabetes management
Telemedicine providers — Toujeo can be prescribed via telehealth in most states, provided the provider conducts an appropriate evaluation and your state does not have a physical examination requirement for insulin prescriptions (most do not). Platforms like Teladoc, MDLive, and endocrinology-specific telehealth services can prescribe Toujeo for established diabetic patients.

Once you have your prescription, the harder problem is finding a pharmacy that has it. That's where FindUrMeds comes in.

Toujeo Side Effects

Like all insulins, Toujeo carries a risk of side effects ranging from common and manageable to rare and serious. Here's what to know:

Most Common Side Effects

Hypoglycemia (low blood sugar) — The most frequent and clinically important side effect of any insulin. Symptoms include shakiness, sweating, dizziness, confusion, and rapid heartbeat. Toujeo's flat profile reduces nocturnal hypoglycemia risk compared to some other basal insulins, but hypoglycemia can still occur — especially if you eat less than usual, exercise more, or accidentally take too much.
Injection site reactions — Redness, itching, or mild swelling at the injection site are common, especially when first starting. Rotating injection sites helps significantly.
Lipodystrophy — Fatty tissue changes (either thickening or thinning) at injection sites with long-term use. Rotating sites reduces risk.
Weight gain — Insulin facilitates glucose uptake into cells, which can lead to modest weight gain, particularly in the early months of therapy. Typically ranges from 1–4 kg in clinical trials.
Edema (fluid retention) — Mild swelling, usually in the hands or feet, can occur when starting insulin therapy. Often resolves on its own.

Less Common but Serious Side Effects

Severe hypoglycemia — Loss of consciousness, seizure, or inability to self-treat. Requires glucagon or emergency intervention. Contact your provider if you experience more than 2 episodes of hypoglycemia requiring assistance per week.
Hypokalemia (low potassium) — Insulin shifts potassium into cells; in patients with kidney disease or on certain medications, this can become clinically significant. Contact your provider if you experience muscle cramps, weakness, or irregular heartbeat.
Allergic reactions — Rare but serious. Whole-body rash, difficulty breathing, or rapid heartbeat after injection require immediate emergency care. A localized rash alone is less urgent but should still be reported to your provider.
Visual changes — Rapid improvement in blood sugar control (common when starting insulin) can temporarily worsen diabetic retinopathy. Contact your provider if you notice sudden vision changes when starting Toujeo.

Side Effects That Typically Improve Over Time

Many patients experience mild injection site discomfort, minor fluid retention, and appetite changes during the first 2–4 weeks on Toujeo. These typically resolve as your body adjusts to the new insulin regimen and as your blood sugar stabilizes. If side effects persist beyond 4 weeks or are significantly affecting your quality of life, let your provider know — dose adjustments or technique changes often help.

This information is for general educational purposes only and does not replace the guidance of your healthcare provider or pharmacist. Every patient's situation is different.

Alternatives to Toujeo

If Toujeo is unavailable, unaffordable, or not the right fit for your situation, several alternatives may be worth discussing with your doctor.

Same-Class Alternatives (Long-Acting Basal Insulins)

Lantus (insulin glargine U-100) — The original glargine insulin; same active ingredient as Toujeo but at 100 units/mL. Available as vials and pens. Note: doses are not interchangeable unit-for-unit with Toujeo.
Basaglar (insulin glargine U-100) — An FDA-approved biosimilar to Lantus from Eli Lilly; typically lower cost than Toujeo and available at most pharmacies. Same concentration and dosing considerations as Lantus.
Rezvoglar (insulin glargine U-100) — Eli Lilly's interchangeable biosimilar to Lantus, approved 2022; even lower list price.
Semglee (insulin glargine U-100) — FDA-interchangeable biosimilar to Lantus; available at significantly reduced cash prices and commonly stocked at major chains.
Tresiba (insulin degludec U-100 and U-200) — Ultra-long-acting insulin with duration exceeding 42 hours; an alternative for patients needing maximum duration flexibility.
Levemir (insulin detemir) — Intermediate to long-acting basal insulin; typically dosed once or twice daily; being discontinued by Novo Nordisk in the US as of 2024 — confirm availability.
Lantus biosimilars — Multiple FDA-approved biosimilars are now available that may offer lower cost access for patients who need glargine-class insulin.

Different-Mechanism Alternatives

For patients whose care team is considering a fundamentally different approach to basal coverage:

GLP-1 receptor agonists with basal activity — Agents like semaglutide (Ozempic/Wegovy) or dulaglutide (Trulicity) provide glucose-lowering through a non-insulin mechanism and may reduce or eliminate the need for basal insulin in some type 2 patients.
Combination GLP-1/basal insulin products — Xultophy (insulin degludec + liraglutide) and Soliqua (insulin glargine + lixisenatide) combine basal insulin with a GLP-1 agonist in a single pen.
SGLT-2 inhibitors — Medications like empagliflozin (Jardiance) or dapagliflozin (Farxiga) work through the kidneys and may be used alongside or instead of insulin in type 2 patients with adequate kidney function.

Any switch from Toujeo to another insulin requires careful dose recalculation and monitoring — do not substitute one insulin for another without your prescriber's explicit guidance.

If you'd prefer to stick with Toujeo, FindUrMeds has a high success rate finding it in stock.

Drug Interactions with Toujeo

Toujeo interacts with a meaningful number of medications — some that increase hypoglycemia risk, some that reduce insulin's effectiveness, and some that mask warning signs of low blood sugar. This is not a complete list; always share your full medication list with your prescribing provider and pharmacist.

Serious Interactions

Other insulins or insulin secretagogues (sulfonylureas: glipizide, glimepiride, glyburide) — Combining basal insulin with sulfonylureas significantly increases hypoglycemia risk. Dose adjustments are almost always required.
Thiazolidinediones (pioglitazone, rosiglitazone) — Can cause fluid retention and worsen heart failure when combined with insulin. Use requires careful monitoring; combination is contraindicated in patients with NYHA Class III or IV heart failure.
Pramlintide (Symlin) — Slows gastric emptying and alters glucose absorption; requires insulin dose reduction when used together.
Beta-blockers (metoprolol, atenolol, propranolol) — Can mask tachycardia, a key warning sign of hypoglycemia. Also may prolong hypoglycemia. Use with caution; sweating (not blocked by beta-blockers) becomes a more important hypoglycemia warning sign.

Moderate Interactions

Corticosteroids (prednisone, methylprednisolone) — Significantly raise blood sugar and may require substantial insulin dose increases during steroid courses.
Atypical antipsychotics (olanzapine, clozapine, quetiapine) — Associated with hyperglycemia; may reduce insulin effectiveness and require dose adjustments.
Fluoroquinolone antibiotics (ciprofloxacin, levofloxacin) — Linked to both hypoglycemia and hyperglycemia; glucose should be monitored more closely during antibiotic courses.
ACE inhibitors (lisinopril, enalapril) — May enhance insulin sensitivity and increase hypoglycemia risk modestly; monitor blood sugar when starting or changing doses.
Diuretics (furosemide, hydrochlorothiazide) — Thiazides in particular may raise blood sugar; loop diuretics can cause electrolyte shifts that complicate insulin therapy.
MAO inhibitors — Can prolong and intensify hypoglycemia; combination generally avoided.

Food and Substance Interactions

Alcohol — Increases hypoglycemia risk, particularly if consumed without adequate food intake. Alcohol inhibits gluconeogenesis (the liver's ability to raise blood sugar), which amplifies insulin's effect. Always eat if drinking, and avoid heavy alcohol use.
Caffeine — May modestly raise blood sugar by stimulating stress hormone release; effects are generally minor but can affect glucose readings.
High-carbohydrate meals — Not a drug interaction per se, but dramatic swings in carbohydrate intake can destabilize blood sugar control; basal insulin alone does not cover mealtime glucose spikes.
Cannabis — Can cause erratic blood sugar responses and impair hypoglycemia recognition; use with caution and inform your diabetes care team.

How to Find Toujeo in Stock

This is the part that matters most — because even with a valid prescription and good insurance, finding Toujeo on a pharmacy shelf near you is not always straightforward. Here's the most efficient approach, from easiest to most time-consuming:

1. Use FindUrMeds — The Fastest Option

FindUrMeds was built specifically for situations like this. Here's how it works:

You submit your prescription details and zip code. Takes about 2 minutes. You tell us what you need — Toujeo SoloStar, Max SoloStar, your dose — and we do the rest.
We contact pharmacies across our 15,000+ location network on your behalf. Our team calls CVS, Walgreens, Rite Aid, Walmart, Kroger, Publix, Costco, Sam's Club, and independent pharmacies in your area — simultaneously, not sequentially.
You get a confirmed location within 24–48 hours. We notify you with the pharmacy name, address, and what they have in stock. You bring your prescription (or have your provider send it electronically) and pick it up. No more calling around. 92% success rate nationwide.

2. Check GoodRx — The Price-Listing-Signals-Stock Trick

Most patients use GoodRx to find coupons — but it's also useful for gauging which nearby pharmacies are most likely to carry Toujeo. Here's why: GoodRx typically only shows pricing at pharmacies that have recently dispensed that medication or have contracted to fill it. If a pharmacy shows up on GoodRx with a price listed for Toujeo SoloStar, that's a reasonably strong signal they stock it. Pharmacies that have never filled it or stopped carrying it often don't appear in GoodRx results for that specific drug.

How to use this: Go to GoodRx.com, search "Toujeo SoloStar," and enter your zip code. Sort by proximity. The pharmacies that appear with prices are your best bets to call first. This doesn't guarantee stock — but it narrows your list from 20+ pharmacies to 4–6 worth contacting.

3. Check Pharmacy Apps — CVS, Walgreens, Walmart

Major chain pharmacy apps have varying levels of real-time inventory visibility:

CVS app/website: Search for Toujeo in the "Pharmacy" section. CVS's system can sometimes show whether a prescription is available for transfer or pickup, especially if you already have a profile there. Calling the pharmacy directly after identifying your nearest CVS locations through the app is faster than calling corporate.
Walgreens app: Walgreens allows prescription transfers through the app and sometimes flags whether a medication is available at a given location when you initiate a transfer. Start a transfer request and see which locations accept it.
Walmart Pharmacy: Walmart's pharmacy locator online shows participating locations. Walmart pharmacies tend to offer competitive insulin pricing and often stock Toujeo — worth checking Walmart locations even if they're not your typical pharmacy.
Costco and Sam's Club: Both warehouse club pharmacies frequently offer lower cash prices on brand-name insulins and may stock Toujeo even if nearby chain pharmacies don't. Costco's pharmacy is open to non-members for prescription purchases in most states.

4. Call with the Generic Name — And Use This Script

Pharmacy staff are more likely to accurately locate your medication when you use the clinical name. Instead of asking for "Toujeo," try:

"Hi, I'm looking for insulin glargine U-300. Do you have it in stock in any strength — either the SoloStar or the Max SoloStar pen?"

Why this works: Toujeo is sometimes logged in pharmacy systems under its generic name (insulin glargine) alongside its concentration designation (U-300). Some pharmacy technicians may not immediately recognize "Toujeo" by brand name, or may confuse it with Lantus or other glargines. Specifying "U-300" rules out glargine U-100 products. Also ask: "If you don't have it, do you know which nearby pharmacies typically stock it?" — pharmacists often know their local supply landscape.

🔍 Need Toujeo Now?

Don't spend hours calling pharmacies. FindUrMeds contacts 15,000+ locations on your behalf and finds Toujeo in stock near you — usually within 24–48 hours.

Find Toujeo Near You →

92% success rate. Trusted by 200+ healthcare providers.

Frequently Asked Questions

Is Toujeo still in shortage?

As of 2025, Toujeo is not listed on the FDA Drug Shortage Database as an active shortage, and Sanofi has not issued formal allocation notices affecting Toujeo supply in the US market. However, "not in shortage" at the national level does not mean you'll find it on the shelf at your local pharmacy. According to our platform's analysis of Toujeo availability, approximately 1 in 3 retail pharmacy locations that carry insulin do not routinely stock Toujeo — especially the Max SoloStar format. Localized stock issues are common and can occur due to cold-chain delays, regional distribution disruptions, or simply a pharmacy's decision not to carry a lower-volume brand-name product. If your pharmacy tells you Toujeo is backordered, ask for an estimated restock date and contact FindUrMeds to find a nearby location that has it now.

How much does Toujeo cost without insurance?

Without insurance, Toujeo's retail cash price typically ranges from approximately $330–$420 for a 3-pack of SoloStar pens (1,350 total units) and approximately $380–$470 for a 2-pack of Max SoloStar pens (1,800 total units) at major chain pharmacies. GoodRx coupons can reduce this to approximately $270–$360 in many markets. The most impactful savings option for uninsured patients is Sanofi's Insulins Valyou Savings Program, which may allow eligible patients to pay a fixed monthly amount regardless of dose. Patients who are uninsured and meet income thresholds may qualify to receive Toujeo at no cost through Sanofi's Patient Assistance Program. Ask your prescriber's office or call Sanofi directly at 1-888-847-4877 to explore eligibility.

Can I get Toujeo through mail order?

Yes — mail-order pharmacy is a viable and often cost-effective option for Toujeo, particularly for patients on stable, long-term basal insulin therapy who don't need it urgently. Most major insurance plans offer a 90-day mail-order supply at a lower copay than 30-day retail fills. Mail-order pharmacies that handle temperature-sensitive biologics (like insulins) ship Toujeo in insulated cold packs with temperature monitoring; the medication must be kept refrigerated until first use. Express Scripts, CVS Caremark, OptumRx, and Amazon Pharmacy all handle insulin mail orders. Turnaround is typically 5–10 business days, so plan ahead — don't wait until your last pen to place the order. Mail order is generally not the right solution for an urgent, near-term need, which is where FindUrMeds (24–48 hour local pharmacy search) is more useful.

What's the difference between Toujeo and Lantus?

Toujeo and Lantus both contain insulin glargine — the same active ingredient — but at different concentrations. Lantus is U-100 (100 units/mL); Toujeo is U-300 (300 units/mL). This is not a minor formulation difference — it has real clinical implications. First, the doses are not interchangeable unit-for-unit: when switching between Toujeo and Lantus, your prescriber will typically recalculate your dose to account for differences in bioavailability and duration. Second, Toujeo's higher concentration creates a smaller-volume injection and a slower, more extended release — approximately 36 hours of action versus roughly 24 hours for Lantus. Clinical trials showed Toujeo produces lower rates of nocturnal hypoglycemia in some patient populations compared to Lantus. Third, cost and availability differ: Lantus has multiple FDA-approved biosimilars (Basaglar, Semglee, Rezvoglar) that are widely stocked and often significantly cheaper, while Toujeo has no direct substitute at the U-300 concentration. If your doctor prescribed Toujeo specifically, don't substitute Lantus without explicit guidance — the dosing adjustment is essential.

What if my pharmacy is out of Toujeo?

If your pharmacy is out of Toujeo, you have several options — and the right one depends on how urgent the situation is. If you have 5 or more days of supply remaining: ask your pharmacy for an estimated restock date; if it's within a few days and you're stable, waiting may be reasonable. Call FindUrMeds to locate a nearby pharmacy with stock available now — our team typically confirms a location within 24–48 hours. If you have fewer than 3 days of supply: do not wait. Contact FindUrMeds immediately, use the GoodRx availability trick to identify which nearby pharmacies are most likely stocked, and call using the "insulin glargine U-300" script described in the section above. Ask your prescribing provider if a bridge supply of Lantus or a biosimilar glargine is appropriate as a temporary measure — they can prescribe it with specific dose conversion instructions. Do not attempt to substitute one insulin for another on your own, and do not skip doses of basal insulin. Missed basal insulin doses can lead to significant hyperglycemia within 24–36 hours.

Need help finding Toujeo in stock? FindUrMeds contacts pharmacies for you and finds your prescription nearby — usually within 24–48 hours. No more calling around.

Find Toujeo Near You →

FindUrMeds is committed to providing accurate, evidence-based medication information to help patients in the United States manage their prescriptions. This content is for informational purposes only and does not constitute medical advice. Always consult your doctor or pharmacist before making any changes to your medication regimen.

About FindUrMeds: We contact pharmacies on your behalf and find your prescription in stock nearby, usually within 24–48 hours across 15,000+ US pharmacies. Learn how it works →

Toujeo

Findability Score: 60/100